Table 1 Clinical and pathological characteristics.
From: Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?
| Â | Â | Total | No Lymphadenectomy | Lymphadenectomy | p-Wert (Chi2) |
|---|---|---|---|---|---|
Patient number | Â | n = 214 | n = 63 (29.4%) | n = 151 (70.6%) | Â |
Age at surgery | >65 years | 107 (50%) | 46 (43.0%) | 61 (57.0%) | <0.001 |
|  | ≤65 years | 107 (50%) | 17 (15.9%) | 90 (84.1%) |  |
FIGO Stage | I | 171 (79.9%) | 51 (29.8%) | 120 (70.2%) | N.S. |
| Â | II | 15 (7.0%) | 6 (40.0%) | 9 (60.0%) | Â |
| Â | III | 21 (9.8%) | 3 (14.3%) | 18 (85.7%) | Â |
| Â | IV | 7 (3.3%) | 3 (42.9%) | 4 (57.1%) | Â |
WHO Grade | 1 | 134 (62.6%) | 36 (26.9%) | 98 (73.1%) | N.S. |
| Â | 2 | 56 (26.2%) | 18 (32.1%) | 28 (67.9%) | Â |
| Â | 3 | 24 (11.2%) | 9 (37.5%) | 15 (62.5%) | Â |
Lymphangiosis | Negative | 197 (92.1%) | 57 (28.9%) | 140 (71.1%) | N.S. |
| Â | Positive | 17 (7.9%) | 6 (35.3%) | 11 (64.7%) | Â |
Deep myometrial invasion | only endometrium | 34 (15.9%) | 9 (26.5%) | 25 (73.5%) | N.S. |
| Â | <50% | 111 (51.9%) | 31 (27.9%) | 80 (72.1%) | Â |
| Â | >50% | 69 (32.2%) | 23 (33.3%) | 46 (66.7%) | Â |
Cervical involvement | negative | 191 (89.3%) | 55 (28.8%) | 136 (71.2%) | N.S. |
| Â | positive | 23 (10.7%) | 8 (34.8%) | 15 (65.2%) | Â |
Ovarian metastasis | negative | 204 (95.2%) | 61 (29.9%) | 143 (70.1%) | N.S. |
| Â | positive | 10 (4.7%) | 2 (20%) | 8 (80%) | Â |
Obesity | Negative | 137 (64.0%) | 39 (28.5%) | 98 (71.5%) | N.S. |
| Â | Positive | 77 (36.0%) | 24 (31.2%) | 53 (68.8%) | Â |
Diabetes | Negative | 187 (87.4%) | 49 (26.2%) | 138 (73.8%) | <0.05. |
| Â | Positive | 27 (12.6%) | 14 (51.9%) | 13 (48.1%) | Â |
Hypertension | Negative | 126 (58.49) | 25 (19.8%) | 101 (80.2%) | <0.001. |
| Â | Positive | 88 (41.1%) | 38 (43.2%) | 50 (56.8%) | Â |
Adjuvant radiotherapy | Not performed | 138 (64.5%) | 43 (31.2%) | 95 (68.8%) | N.S. |
| Â | performed | 76 (35.5%) | 20 (26.2%) | 56 (73.3%) | Â |